Platelet-Derived EV Composites for Bone Formation and Resorption Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for bone degeneration diseases, such as osteoporosis and osteoarthritis, are associated with side effects, risks, high costs, and accessibility issues, and emerging therapies like gene therapy and stem cell therapy have unknown long-term safety and efficacy.
Innovation Solution
The use of platelet-derived extracellular vesicles (EVs) and composite materials comprising them for bone replacement and rebuilding, which stimulate osteoblast activity and inhibit osteoclast activity, are developed to address bone degeneration diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bone-building medications (bisphosphonates, anabolic agents) are used to treat bone degeneration, then bone formation is stimulated and bone resorption is reduced, but side effects occur including gastrointestinal issues, musculoskeletal pain, and rare but serious conditions like osteonecrosis of the jaw and atypical femoral fractures
Solution Approach 1:
The patent extracts and isolates specific bioactive molecules (growth factors, cytokines, extracellular vesicles) from platelets and other cellular sources to create a purified therapeutic preparation. This extraction process removes unwanted cellular components while retaining the beneficial bioactive substances, thereby reducing side effects while maintaining bone formation stimulation effects.
Solution Approach 2:
The patent modifies the chemical and biological parameters of the therapeutic agent by controlling the concentration, purity, and composition of the isolated bioactive molecules. By optimizing these parameters, the therapy achieves effective bone regeneration with reduced toxicity and fewer side effects compared to conventional medications.
2Strength
If surgical interventions (bone grafting, joint replacement) are applied for severe bone loss or fracture, then bone structure and function are restored, but the procedures are invasive, costly, and require recovery time
Solution Approach 1:
The patent replaces mechanical surgical interventions (bone grafting, joint replacement) with a biological therapy using bioactive molecules that stimulate natural bone regeneration. This substitution eliminates the need for invasive surgery while achieving similar or superior bone restoration through cellular and molecular mechanisms.
Solution Approach 2:
The therapy enables the body's own bone-regenerating cells to perform the repair function by providing them with the necessary bioactive signals. This self-service approach eliminates the need for external surgical intervention, reducing complexity and recovery requirements while maintaining effective bone restoration.
3Productivity
If emerging therapies (gene therapy, stem cell therapy) are used to treat bone degeneration, then bone regeneration potential is enhanced, but long-term safety and efficacy are unknown
Solution Approach 1:
The patent uses platelet-derived bioactive molecules that are naturally degraded and metabolized by the body, avoiding the need for permanent genetic modification or long-lasting stem cell implants. These short-living molecular agents provide temporary but effective stimulation of bone regeneration with well-understood safety profiles, eliminating the long-term safety uncertainties associated with gene and stem cell therapies.
4Quantity of substance
If pharmacological therapies are used to treat bone degeneration, then bone density is improved, but not all patients respond equally well and some experience dependency on long-term medication use
Solution Approach 1:
The patent segments the complex bone regeneration process into multiple biological pathways and cellular mechanisms, allowing for a more nuanced and adaptable therapy. By incorporating diverse bioactive molecules that act through different mechanisms, the therapy can accommodate varying patient responses and personalize treatment effectiveness.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are platelet-derived extracellular vesicles (EVs), and composite materials comprising them, for use as bone replacement material and/or as bone rebuilding material. Also, methods of production, medical uses and kits are disclosed.